Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Durable Responses Seen With Barzolvolimab in CSU Trial
AMSTERDAM — Patients with chronic spontaneous urticaria (CSU) experienced early and sustained improvements in symptom scores on treatment with barzolvolimab, during the 52-week follow-up of an ongoing phase 2 study. Moreover, in the study, barzolvolimab, an anti-KIT monoclonal antibody that…
English